Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elevated LDL-C of \>3.0 mmol/L and \<5.7 mmol/L~* Fasting triglyceride concentration ≤2.8 mmol/L~* Body weight \>60.0 kg; body mass index (BMI) between 19.00 kg/m2 and \<35.00 kg/m2~* Adequate blood counts, liver and renal function~* May not received any lipid lowering drug/agent within the 30 days prior to the screening~* Non-smokers for at least 3 months~* Women of child-bearing potential must have a negative pregnancy test, cannot be breast feeding, and must use an adequate method of birth control~* Males agree to use appropriate contraception~* Willing and able to comply with protocol-required visit schedule and visit requirements and provide written informed consent~Exclusion Criteria:~* Known hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection~* Multiple drug allergies or know sensitivity to oligonucleotide~* History of drug abuse and/or alcohol abuse~* Receiving an investigational agent within 3 months prior to study drug administration~* Subjects with safety laboratory test results deemed clinical significant by the Investigator;~* Received prescription drugs within 4 weeks of first dosing~* Subjects who have donated more than 500 mL of blood within the 3 months prior to ALN-PCS02 or placebo administration;~* Received megadose vitamin therapy or dietary supplements within 4 weeks prior to screening~* Subjects who have used prescription drugs within 4 weeks of first dosing~* Considered unfit for the study by the Principal Investigator~* Employee or family member of the sponsor or the clinical study site personnel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ALN-PCS02 (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).